In Brief:
Anti-CGRP-mAbs ability to directly alter headache-related peripheral functions in meningeal nociceptors, cerebral, and meningeal blood vessels and possible immune cells, which indirectly alter excitability and responsiveness of neurons in brain areas involved in migraine pathophysiology, is the most likely mechanisms by which this class of drugs prevents migraine.